Related Experiment Video
Updated: Jun 14, 2025
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Perforin 1 in Cancer: Mechanisms, Therapy, and Outlook
Xiaoya Guan1,2, Huina Guo1,2, Yujia Guo1,2
1Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan 030001, China.
Abstract:
PRF1 (perforin 1) is a key cytotoxic molecule that plays a crucial role in the killing function of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). Recent studies have focused on PRF1's role in cancer development, progression, and prognosis. Studies have shown that aberrant PRF1 expression has a significant role to play in cancer development and progression. In some cancers, high expression of the PRF1 gene is associated with a better prognosis for patients, possibly because it helps enhance the body's immune response to tumors. However, some studies have also shown that the absence of PRF1 may make it easier for tumors to evade the body's immune surveillance, thus affecting patient survival. Furthermore, recent studies have explored therapeutic strategies based on PRF1, such as enhancing the ability of immune cells to kill cancer cells by boosting PRF1 activity. In addition, they have improved the efficacy of immunotherapy by modulating its expression to enhance the effectiveness of the treatment. Based on these findings, PRF1 may be a valuable biomarker both for the treatment of cancer and for its prognosis in the future. To conclude, PRF1 has an important biological function and has clinical potential for the treatment of cancer, which indicates that it deserves more research and development in the future.
Insights
Perforin 1 (PRF1) is vital for immune cell cancer killing. Aberrant PRF1 expression impacts cancer development and prognosis, showing potential as a therapeutic target and biomarker for cancer treatment.
Area of Science:
- Immunology
- Oncology
Background:
- Perforin 1 (PRF1) is a critical cytotoxic molecule essential for natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) function.
- Aberrant PRF1 expression is increasingly recognized for its significant role in cancer development and progression.
Purpose of the Study:
- To explore the multifaceted role of PRF1 in cancer, including its impact on tumor development, progression, and patient prognosis.
- To investigate the potential of PRF1 as a therapeutic target and prognostic biomarker in oncology.
Main Methods:
- Review of recent studies investigating PRF1 expression in various cancer types.
- Analysis of the correlation between PRF1 levels and patient outcomes, including survival rates.
- Examination of emerging therapeutic strategies targeting PRF1 activity and expression.
Main Results:
- High PRF1 gene expression is linked to better patient prognosis in some cancers, potentially by enhancing anti-tumor immune responses.
- Absence of PRF1 may facilitate tumor immune evasion, negatively impacting patient survival.
- Therapeutic strategies enhancing PRF1 activity show promise in boosting immune cell-mediated cancer killing and improving immunotherapy efficacy.
Conclusions:
- PRF1 plays a crucial biological role in cancer immunity and progression.
- PRF1 holds significant potential as a valuable biomarker for cancer prognosis and a target for novel cancer therapies.
- Further research and development of PRF1-based strategies are warranted for future clinical applications in cancer treatment.
More Related Videos
11:04An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
Published on: January 13, 2023
08:02Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
Published on: May 14, 2021
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...